WallStreetZenWallStreetZen

NASDAQ: CYCC
Cyclacel Pharmaceuticals Inc Stock

$1.65+0.11 (+7.14%)
Updated Jul 12, 2024
CYCC Price
$1.65
Fair Value Price
N/A
Market Cap
$2.41M
52 Week Low
$1.30
52 Week High
$13.20
P/E
-0.07x
P/B
-1.09x
P/S
6.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$449.00k
Earnings
-$19.70M
Gross Margin
100%
Operating Margin
-5,061.69%
Profit Margin
-4,420.3%
Debt to Equity
-3.8
Operating Cash Flow
-$10M
Beta
0.85
Next Earnings
Aug 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CYCC Overview

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CYCC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CYCC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CYCC is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
CYCC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more CYCC due diligence checks available for Premium users.

Be the first to know about important CYCC news, forecast changes, insider trades & much more!

CYCC News

Valuation

CYCC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.07x
Industry
-12.81x
Market
32.2x

CYCC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-1.09x
Industry
6.45x

CYCC's financial health

Profit margin

Revenue
$29.0k
Net Income
-$2.9M
Profit Margin
-10,158.6%
CYCC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CYCC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$6.2M
Liabilities
$8.4M
Debt to equity
-3.8
CYCC's short-term liabilities ($8.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYCC's short-term assets ($4.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYCC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CYCC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$483.0k
Investing
$0.0
Financing
-$79.0k
CYCC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CYCC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CYCC$2.41M+7.14%-0.07x-1.09x
NBY$2.52M+4.48%-0.02x15.74x
WINT$2.26M-0.78%-0.11x0.15x
PHIO$2.58M-13.60%-0.17x0.46x
CING$2.60M-10.42%-0.02x0.81x

Cyclacel Pharmaceuticals Stock FAQ

What is Cyclacel Pharmaceuticals's quote symbol?

(NASDAQ: CYCC) Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol CYCC. Cyclacel Pharmaceuticals stock quotes can also be displayed as NASDAQ: CYCC.

If you're new to stock investing, here's how to buy Cyclacel Pharmaceuticals stock.

What is the 52 week high and low for Cyclacel Pharmaceuticals (NASDAQ: CYCC)?

(NASDAQ: CYCC) Cyclacel Pharmaceuticals's 52-week high was $13.20, and its 52-week low was $1.30. It is currently -87.5% from its 52-week high and 26.92% from its 52-week low.

How much is Cyclacel Pharmaceuticals stock worth today?

(NASDAQ: CYCC) Cyclacel Pharmaceuticals currently has 1,463,259 outstanding shares. With Cyclacel Pharmaceuticals stock trading at $1.65 per share, the total value of Cyclacel Pharmaceuticals stock (market capitalization) is $2.41M.

Cyclacel Pharmaceuticals stock was originally listed at a price of $153,972.00 in May 5, 2004. If you had invested in Cyclacel Pharmaceuticals stock at $153,972.00, your return over the last 20 years would have been -100%, for an annualized return of -43.57% (not including any dividends or dividend reinvestments).

How much is Cyclacel Pharmaceuticals's stock price per share?

(NASDAQ: CYCC) Cyclacel Pharmaceuticals stock price per share is $1.65 today (as of Jul 12, 2024).

What is Cyclacel Pharmaceuticals's Market Cap?

(NASDAQ: CYCC) Cyclacel Pharmaceuticals's market cap is $2.41M, as of Jul 13, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cyclacel Pharmaceuticals's market cap is calculated by multiplying CYCC's current stock price of $1.65 by CYCC's total outstanding shares of 1,463,259.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.